Shopping Cart
- Remove All
Your shopping cart is currently empty
Recommended products
- New Product
- Wikimole
IMB-XMA0038
- Product IDT71725
- Signaling Pathway
- Target
Azalanstat
- Product IDT25127
- Signaling Pathway
- Target
Thymectacin
- Product IDT24881
- Signaling Pathway
- Target
SAR-114137
- Product IDT28658
- Signaling Pathway
- Target
ZTZ240
- Product IDT29236
- Signaling Pathway
- Target
Signaling Pathway / research field
Empowering numerous drug development teams
Tumor/Cancer
Cancer is a serious disease caused by the unrestricted proliferation of cells in the body that lose normal growth control. It can occur in any part of the body, such as the lungs, breasts, colon, and skin. Cancer is one of the major threats to global health, causing millions of deaths each year and bringing profound pain and economic burdens to patients and their families. In recent years, there has been significant progress in the field of cancer treatment, especially in areas such as targeted therapy and immunotherapy. Researchers are working hard to discover new biomarkers and treatment methods to further improve treatment effectiveness.
Immune and Inflammatory
Immune and inflammatory diseases constitute a diverse and complex array of health problems, primarily involving abnormal reactions of the immune system. These diseases include autoimmune conditions such as rheumatoid arthritis and systemic lupus erythematosus, as well as conditions like asthma and allergic diseases, which are caused by the immune system's overreaction to environmental factors. The complexity of these diseases stems from their pathogenesis, involving a combination of genetic factors, environmental influences, and lifestyle choices. They pose not only a challenge to individual health but also place a significant burden on public health systems.In recent years, the medical research field has focused on deciphering and modulating the mechanisms of the immune system to develop more effective treatment methods. This includes precisely regulating immune responses, developing innovative drugs targeting specific immune pathways, and exploring new strategies for mitigating inflammatory responses.
Neurodegenerative Diseases
Neurodegenerative diseases are a group of conditions that affect the nervous system, primarily characterized by the gradual degeneration and death of nerve cells. These diseases include Alzheimer's disease, Parkinson's disease, Huntington's disease, and others, often leading to cognitive decline, impaired motor skills, and other neurological dysfunctions. With the aging of the global population, the incidence of these diseases is gradually increasing, posing significant challenges to patients and their families. The exact causes of neurodegenerative diseases remain a focal point of scientific research. It is currently believed that genetic factors, environmental influences, and lifestyle choices may all play a role in the development of these diseases. Due to the varying symptoms and progression patterns of these diseases, research and treatment present a high level of complexity.
Endocrine and Metabolism
Endocrine and metabolic diseases, such as diabetes, thyroid disorders, adrenal diseases, and obesity, are caused by abnormalities in endocrine gland functions or disruptions in metabolic processes. The endocrine system, which includes the thyroid, pancreas, and adrenal glands, regulates numerous physiological functions in the body by secreting hormones. These hormones directly affect the body's metabolic processes, such as the synthesis and breakdown of substances. When this balance is disrupted, it can lead to abnormal energy metabolism, severely affecting patients' daily lives and health. In recent years, research has focused on developing new therapeutic drugs for these diseases, optimizing existing hormone replacement therapies, and gaining a deeper understanding of the impact of genetic and lifestyle factors on these diseases. The goal is to improve treatment efficacy, reduce drug side effects, and enhance patients' quality of life.
Cardiovascular Diseases
Cardiovascular diseases refer to a group of conditions affecting the heart and blood vessel system, including coronary artery disease (leading to angina and myocardial infarction), hypertension, heart failure, cerebrovascular diseases, and others. These diseases are often closely associated with impaired vascular health, such as atherosclerosis, and lifestyle factors such as unhealthy diet, lack of exercise, smoking, and excessive drinking are also major contributors. Cardiovascular diseases are one of the leading health problems worldwide and are among the primary causes of death in adults. Prevention and treatment of cardiovascular diseases require not only lifestyle changes but also play a crucial role in pharmacotherapy and surgical interventions. Researchers are dedicated to deciphering the pathogenesis of cardiovascular diseases and developing and testing new drugs and treatment strategies to more effectively address the challenges posed by these diseases.
Infectious Diseases
Infectious diseases are illnesses caused by various pathogens such as bacteria, viruses, fungi, or parasites, and they can be transmitted through various means including air, food, water, or direct human contact. Common infectious diseases include influenza, HIV/AIDS, tuberculosis, malaria, and novel coronavirus diseases. These diseases pose a serious threat to global public health.
Organoids and Stem Cells
Organoids are three-dimensional miniature tissue structures cultured in a laboratory environment, capable of mimicking the cellular composition, structure, and function of real organs, and have become an important tool in modern biomedical research. They play a key role in constructing disease models, drug screening, and toxicity testing. Organoids typically originate from stem cells, which can differentiate into various cell types under specific culture conditions, eventually forming organoids. As the core of this process, stem cells have remarkable self-renewal capabilities and the potential to differentiate into various cell types.
Compound Libraries
We can provide a library of over 800 small molecule compounds with diverse types, structures, sources, and scales for high-throughput screening in new drug discovery, helping drug developers discover promising compounds.
Cutting-edge information
Assist in reducing research and development investment
WIKIMOLE—Liproxstatin-1
Liproxstatin-1 (Product No. T2376, CAS 50455-15-9) is a potent and selective ferroptosis inhibitor. Liproxstatin-1 can protect cells from ferroptosis induced by ferroptosis inducers such as Erastin and RSL3.
08 Dec 2024
See More 
Order Now and Get a 2025 Calendar–Limited Time Offer!
We’re excited to announce a special giveaway for our U.S. customers! Place an order with TargetMol and receive a free 2025 calendar with your shipment.
Hurry—this is a first-come, first-served offer, and quantities are limited. Once they’re gone, they’re gone! Don’t miss your chance to kick off the new year with this exclusive gift.
Place your order and get ready to make 2025 a year of new discoveries!
24 Oct 2024
See More 
WIKIMOLE—5-Fluorouracil , Staurosporine , Ruxolitinib
5-Fluorouracil (5-FU) is a uracil analog and inhibitor of DNA synthesis, exhibiting antitumor activity by affecting pyrimidine synthesis through thymidylate synthase inhibition; it induces apoptosis and autophagy.
18 Oct 2024
See More 
Come to See TargetMol Upcoming Events
Join TargetMol at DOT booth #110 to explore our latest offerings and innovations in drug discovery and chemical biology.
Visit TargetMol at SFN booth #1012 to discover our cutting-edge products and solutions tailored for neuroscience research.
29 Sep 2024
See More 
WIKIMOLE—Trametinib
Trametinib is a highly selective MEK inhibitor that blocks the proliferation of tumor cells by inhibiting the key enzymes MEK1/2 in the RAS-RAF-MEK-ERK signaling pathway. It can also activate autophagy and induce apoptosis, playing a crucial role in the treatment of cancers with BRAF mutations. Trametinib is commonly used in research related to the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
13 Sep 2024
See More 
TargetMol to Attend The 83rd Annual Meeting of the Japanese Cancer Association
TargetMol will be participating in The 83rd Annual Meeting of the Japanese Cancer Association (JCA), which will take place from September 19-21, 2024, in Fukuoka, Japan. This prestigious conference brings together leading researchers, clinicians, and industry professionals to explore the latest advancements in cancer research and treatment.
Date: September 19 (thu)-21(sat), 2024
Location: Fukuoka International Congress Center, Marine Messe Fukuoka Hall B (マリンメッセ福岡Ｂ館, 〒812-0031 福岡県福岡市博多区沖浜町2−1)
Theme: Cancer Research for Perfect Cure
TargetMol Booth: No.1
Conference Link: https://site.convention.co.jp/jca2024/
At this year’s event, TargetMol will showcase our extensive range of cutting-edge small molecules and bioactive compounds that support cancer research, drug discovery, and development.We invite all attendees to visit us at Booth No. 1 to learn more about our offerings and explore potential collaborations.
11 Sep 2024
See More 
WIKIMOLE—Necrostatin-1（Nec-1）
Necrostatin-1 (Nec-1)(Product No. T1847, CAS 4311-88-0) is a necroptosis inhibitor targeting RIPK1 and also an IDO inhibitor. Necrostatin-1 consists of a benzene ring, an aminothiazole ring, and an amide group. These structural features enable it to specifically bind to RIPK1 and inhibit its activity.
06 Sep 2024
See More 
TargetMol Proud to be a Gold Sponsor at the 2024 Harvard Chinese Life Science Annual Symposium
TargetMol will be a Gold Sponsor of the prestigious 2024 Harvard Chinese Life Science Annual Symposium, taking place on September 14, 2024. This annual event brings together leading researchers, industry professionals, and innovators from the global life sciences community, with a focus on advancements in biomedical research, biotechnology, and pharmaceutical sciences.
5 September 2024
See More Citation
From research institutions to leading pharmaceutical companies, our products & services empower scientists to achieve groundbreaking discoveries. Explore citations from top-tier journals that validate the quality and impact of our products.
2024, 627(8002):149-156.
Multisensory gamma stimulation promotes glymphatic clearance of amyloid
2023, 33(12):904-922.
Mannose antagonizes GSDME-mediated pyroptosis through AMPK activated by metabolite GlcNAc-6P
2023, 33(12):940-951.
Cryo-EM structures of human organic anion transporting polypeptide OATP1B1
2023, 33(11):821-834.
Maternal aging increases offspring adult body size via transmission of donut-shaped mitochondria
2023, 33(1):46-54.
Structural basis of signaling regulation of the human melanocortin-2 receptor by MRAP1
2023, 41(7):1276-1293.e11.
Exhaustion-associated cholesterol deficiency dampens the cytotoxic arm of antitumor immunity
2023, 186(13):2929-2949.e20.
Distinct longevity mechanisms across and within species and their association with aging
2023, 624(7991):425-432.
A novel antidiuretic hormone governs tumour-induced renal dysfunction
2023, 624(7992):663-671.
Recognition of methamphetamine and other amines by trace amine receptor TAAR1
2023, 624(7992):672-681.
Ligand recognition and G protein coupling of trace amine receptor TAAR1
2023, 621(7977):188-195.
CRISPR screens decode cancer cell pathways that trigger γδ T cell detection
2023, 620(7974):676-681.
GPCR activation and GRK2 assembly by a biased intracellular agonist
2022 Jan 17;61(3):e202113515.
Multiplexed Small-Molecule-Ligand Binding Assays by Affinity Labeling and DNA Sequence AnalysisY
2022, 41(1):181-195.e9.
Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma
2022, 32(7):687-690.
The structure of erastin-bound xCT–4F2hc complex reveals molecular mechanisms underlying erastin-induced ferroptosis
2022, 32(3): 288-301.
Cholesterylation of Smoothened is a calcium-accelerated autoreaction involving an intramolecular ester intermediateCitation
- 2024, 627(8002):149-156.Multisensory gamma stimulation promotes glymphatic clearance of amyloid
- 2023, 33(12):904-922.Mannose antagonizes GSDME-mediated pyroptosis through AMPK activated by metabolite GlcNAc-6P
- 2023, 33(12):940-951.Cryo-EM structures of human organic anion transporting polypeptide OATP1B1
- 2023, 33(11):821-834.Maternal aging increases offspring adult body size via transmission of donut-shaped mitochondria
- 2023, 33(1):46-54.Structural basis of signaling regulation of the human melanocortin-2 receptor by MRAP1
- 2023, 41(7):1276-1293.e11.Exhaustion-associated cholesterol deficiency dampens the cytotoxic arm of antitumor immunity
- 2023, 186(13):2929-2949.e20.Distinct longevity mechanisms across and within species and their association with aging
- 2023, 624(7991):425-432.A novel antidiuretic hormone governs tumour-induced renal dysfunction
- 2023, 624(7992):663-671.Recognition of methamphetamine and other amines by trace amine receptor TAAR1
- 2023, 624(7992):672-681.Ligand recognition and G protein coupling of trace amine receptor TAAR1
- 2023, 621(7977):188-195.CRISPR screens decode cancer cell pathways that trigger γδ T cell detection
- 2023, 620(7974):676-681.GPCR activation and GRK2 assembly by a biased intracellular agonist
- 2022 Jan 17;61(3):e202113515.Multiplexed Small-Molecule-Ligand Binding Assays by Affinity Labeling and DNA Sequence AnalysisY
- 2022, 41(1):181-195.e9.Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma
- 2022, 32(7):687-690.The structure of erastin-bound xCT–4F2hc complex reveals molecular mechanisms underlying erastin-induced ferroptosis
- 2022, 32(3): 288-301.Cholesterylation of Smoothened is a calcium-accelerated autoreaction involving an intramolecular ester intermediate
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.
What Our Customer Says
Targetmol offers a wide range of high-quality products. The ordering process is seamless and the delivery is always prompt.What Our Customer Says
Our lab has frequently used the screening and compound-providing services from TargetMol. They have a professional understanding of drug development and pharmacology. Communication with them has always been smooth, and we have received prompt feedback. This efficient cooperation has helped our lab discover small-molecule lead compounds for GPCR drug targets. TargetMol has consistently solved our research challenges, and we look forward to a long-term partnership with them.What Our Customer Says
We have been purchasing compounds through TargetMol for many years now with many satisfied customers. The excellent quality of the products and short delivery time especially from EU stock stick out. Furthermore, we have good experience with TargetMol’s synthesis capabilities.What Our Customer Says
I have ordered several small molecule inhibitors from TargetMol, such as CB89, RSL-3, rebastinib, EPZ6438 and others. These inhibitors have high quality as committed and they showed the specific inhibitory functions in both in vitro and in vivo experiments.What Our Customer Says
Tebubio is delighted of the partnership with TargetMol, facilitating the access of researchers to their molecules throughout Europe and the UK. TargetMol offers an unbelievable Life Sciences catalog with high-quality products such as inhibitors, compounds, natural products and libraries among others.The flexibility in amount supply, from small to large quantities is perfectly fitting with the needs of the European Research Community.What Our Customer Says
We have worked with Targetmol for a couple of years in the Swiss market and our successful partnership has resulted in the fast growth of the business. We look forward to a long-lasting collaboration.